Improving Survivorship and Health-related Quality of Life in Patients With Primary Brain Tumours

Launched by ROYAL COLLEGE OF SURGEONS, IRELAND · Aug 22, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the effects of radiotherapy (a type of cancer treatment using radiation) on hormone function and quality of life in adults who have been treated for primary brain tumors. Researchers want to find out how common hormone deficiencies (called hypopituitarism) are in these patients and how these deficiencies might affect their overall health and well-being. They will also explore if treating these hormone deficiencies can improve patients' quality of life and mental functioning.

To participate in this study, individuals must be at least 18 years old, have a history of a primary brain tumor treated with radiotherapy, and have completed their treatment at least a year ago. Participants will be asked to share their experiences and may undergo tests to assess their hormone levels. This study is important because it aims to fill a gap in our knowledge about the long-term effects of brain tumor treatments and ensure that survivors receive the care they need for a better quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (at least 18 years old) with a history of a primary, non-pituitary brain tumour which was previously treated with radiotherapy.
• • Participants must have been at least 16 years old at the time of undergoing radiotherapy.
• • A minimum of one year has elapsed since radiotherapy was completed.
• • Capacity and willingness to provide informed consent.
• Exclusion Criteria:
• • Diagnosed with malignant astrocytic brain tumour with life expectancy of less than six months.
• • Brain tumour infiltration of the hypothalamus or pituitary pre-operatively.
• • Previously diagnosis of hypopituitarism.
• • Oral glucocorticoid use within the last three months.
• • Pregnant or breastfeeding women at the time of recruitment.
• • Unable to provide informed consent for inclusion in this study.
• • Opinion of the radiation oncology or research team that participation in the study is not in the best interest of the patient for any reason.